TWST

Twist Bioscience Corporation

$132.13

-2.37%
SectorHealthcareIndustryBiotechnologyCountryUnited States

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Source: Yahoo Finance
AI summary

Price & performance

1M-17.3%
3M+5.8%
YTD+307.9%
1Y+326.8%
52-week range—
Beta2.42
Full chart and returns against a benchmark

Q-Score

73/ 100

Quality against peers; 50 is the peer median.

Growth73
Risk61
Performance83
Valuation44
Profitability55
Leverage73
Sentiment17
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$376.6M+20.3%
Net income-$77.7M
Net margin-20.6%+46.1 pts
Historical fundamentals

Revenue exposure

Americas60%
EMEA33%
Asia Pacific7%
Largest customer10%
Regions, segments, customers and suppliers

Valuation

TWSTIndustryP/E—89.69P/S20.2911.88EV/EBITDA—67.10P/B19.656.22PEG—4.02
Dividend yield0.00%
Every valuation metric

Earnings

Nov 12next report, before the open
EPS estimate$-0.20
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate